Landscape Capital Management L.L.C. Purchases 1,313 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Landscape Capital Management L.L.C. increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 10.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,554 shares of the medical device company’s stock after acquiring an additional 1,313 shares during the period. Landscape Capital Management L.L.C.’s holdings in Tandem Diabetes Care were worth $575,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in shares of Tandem Diabetes Care in the third quarter valued at $29,000. ORG Wealth Partners LLC bought a new stake in Tandem Diabetes Care during the 3rd quarter worth about $30,000. ORG Partners LLC acquired a new stake in Tandem Diabetes Care in the 2nd quarter valued at about $31,000. Waldron Private Wealth LLC acquired a new position in shares of Tandem Diabetes Care during the third quarter worth approximately $50,000. Finally, Headlands Technologies LLC grew its stake in shares of Tandem Diabetes Care by 110.0% during the second quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company’s stock valued at $83,000 after purchasing an additional 1,079 shares during the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the topic of several research reports. UBS Group raised Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Royal Bank of Canada initiated coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price target on the stock. Robert W. Baird dropped their price objective on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a report on Thursday, November 7th. Barclays lifted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Canaccord Genuity Group started coverage on shares of Tandem Diabetes Care in a research note on Thursday, August 8th. They set a “buy” rating and a $57.00 price target for the company. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $30.81 on Friday. The company has a market cap of $2.02 billion, a PE ratio of -15.96 and a beta of 1.36. The firm has a 50-day moving average of $36.16 and a 200-day moving average of $41.26. Tandem Diabetes Care, Inc. has a one year low of $18.45 and a one year high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. During the same quarter in the previous year, the business earned ($0.38) earnings per share. The business’s revenue was up 31.4% compared to the same quarter last year. As a group, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current year.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the director now directly owns 195,190 shares of the company’s stock, valued at $5,855,700. The trade was a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.